Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686987 | 0.91 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CA2RARBESR1 | |
| SCHEMBL9219490 | 0.91 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CA2RARBESR1 | |
| SCHEMBL6670812 | 0.91 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CA2RARBESR1 | |
| SCHEMBL83869 | 0.87 | CA2 (0.65) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL3031496 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL10841583 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL1441024 | 0.84 | CA2 (0.52) | ALDH1A1HSD17B10HPGDCA2PLK1 | |
| SCHEMBL10568421 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28990998 | 0.84 | CA2 (0.62) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL9839955 | 0.84 | CA2 (0.62) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-4505549-A | BLUE ANTHRAQUINONE DYES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-03-19 | — | — | US | disclosed |
| US-4477660-A | 7-(S)-Acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0120463-A2 | Anthraquinone dyes and liquid crystal compositions including the same | HITACHI, LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
| US-4474879-A | Process for 3-hydroxymethyl cephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| US-4459405-A | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| EP-0109301-A2 | 7-(S)-acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| EP-0109300-A2 | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4436596-A | N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4434072-A | PLEOCHROIC ANTHRAQUINONE DYE | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1984-02-28 | — | — | US | disclosed |
| EP-0087248-A1 | Liquid crystal composition containing azo dyes | MITSUBISHI KASEI CORPORATION (JP) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885HSD17B10 467/4885HPGD 3159/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885HSD17B10 363/4885HPGD 1951/4885 |
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | ALDH1A1 151/4885HSD17B10 339/4885HPGD 276/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | ALDH1A1 151/4885HSD17B10 339/4885HPGD 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.